Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. https://doi.org/10.3322/caac.21601.

Article  PubMed  Google Scholar 

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.

Article  PubMed  Google Scholar 

Benson AB, Venook AP, Al Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. https://doi.org/10.6004/jnccn.2021.0012.

Article  PubMed  Google Scholar 

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel Rinkes I, Ledermann JA, et al. European organisation for research and treatment of cancer (EORTC), gastro-intestinal tract cancer group; arbeitsgruppe lebermetastasen und tumoren in der chirurgischen arbeitsgemeinschaft onkologie (ALM-CAO); national cancer research institute colorectal clinical study group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9):djx15. https://doi.org/10.1093/jnci/djx015.

Article  Google Scholar 

Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an amsterdam colorectal liver met registry (AmCORE) based study. Cancers (Basel). 2021;13(11):2769. https://doi.org/10.3390/cancers13112769.

Article  Google Scholar 

Puijk RS, Dijkstra M, van den Bemd BAT, Ruarus AH, Nieuwenhuizen S, Geboers B, et al. Improved outcomes of thermal ablation for colorectal liver metastases: a 10 year analysis from the prospective amsterdam CORE registry (AmCORE). Cardiovasc Intervent Radiol. 2022. https://doi.org/10.1007/s00270-022-03152-9.

Article  PubMed  PubMed Central  Google Scholar 

Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. EPOCH investigators radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01839.

Article  PubMed  Google Scholar 

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–94. https://doi.org/10.1200/JCO.2010.28.5643.

CAS  Article  PubMed  Google Scholar 

Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? a large single-center experience of 302 patients. Ann Surg Oncol. 2015;22(3):794–802. https://doi.org/10.1245/s10434-014-4164-x.

Article  PubMed  Google Scholar 

Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol. 2015;6(2):134–42. https://doi.org/10.3978/j.issn.2078-6891.2014.109.94.

Article  PubMed  PubMed Central  Google Scholar 

Hickey R, Lewandowski RJ, Prudhomme T, Ehrenwald E, Baigorri B, Critchfield J, et al. 90Y Radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016;57(5):665–71. https://doi.org/10.2967/jnumed.115.166082.

CAS  Article  PubMed  Google Scholar 

White J, Carolan-Rees G, Dale M, Morgan HE, Patrick HE, See TC, et al. Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases. Clin Oncol (R Coll Radiol). 2019;31(1):58–66. https://doi.org/10.1016/j.clon.2018.09.002.

CAS  Article  Google Scholar 

Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, et al. On behalf of the CIRT steering committee; On behalf of the CIRT principal investigators. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35. https://doi.org/10.1007/s00270-020-02642-y.

Article  PubMed  Google Scholar 

Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13(1):27–36. https://doi.org/10.1016/j.clcc.2013.11.010.

Article  PubMed  Google Scholar 

Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget. 2017;8(23):37912–22. https://doi.org/10.18632/oncotarget.16007.

Article  PubMed  PubMed Central  Google Scholar 

Kurilova I, Beets-Tan RGH, Flynn J, Gönen M, Ulaner G, Petre EN, et al. Factors affecting oncologic outcomes of 90Y radioembolization of heavily pre-treated patients with colon cancer liver metastases. Clin Colorectal Cancer. 2019;18(1):8–18. https://doi.org/10.1016/j.clcc.2018.08.004.

Article  PubMed  Google Scholar 

Mokkarala M, Noda C, Malone C, Ramaswamy R, Akinwande O. Comparison of response and outcomes of drug-eluting bead chemoembolization (DEB-TACE) versus radioembolization (TARE) for patients with colorectal cancer liver metastases. Anticancer Res. 2019;39(6):3071–7. https://doi.org/10.21873/anticanres.13442.

CAS  Article  PubMed  Google Scholar 

Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. PLoS ONE. 2015;10(10):e0139940. https://doi.org/10.1371/journal.pone.0139940.eCollection.

Article  PubMed  PubMed Central  Google Scholar 

Levy J, Zuckerman J, Garfinkle R, Acuna SA, Touchette J, Vanounou T, et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB (Oxford). 2018;20(10):905–15. https://doi.org/10.1016/j.hpb.2018.04.001.

Article  Google Scholar 

Zhao JJ, Tan E, Sultana R, Syn NL, Da Zhuang K, Leong S, et al. Intra-arterial therapy for unresectable colorectal liver metastases: a meta-analysis. J Vasc Interv Radiol. 2021;32(11):1536-1545.e38. https://doi.org/10.1016/j.jvir.2021.05.032.

Article  PubMed  Google Scholar 

Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

CAS  PubMed  Google Scholar 

Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. Surg Oncol. 2017;26(3):268–75. https://doi.org/10.1016/j.suronc.2017.05.003.

Article  PubMed  Google Scholar 

Pereira PL, Iezzi R, Manfredi R, Carchesio F, Bánsághi Z, Brountzos E, et al. The CIREL cohort: a prospective controlled registry studying the real-life use of irinotecan-loaded chemoembolisation in colorectal cancer liver metastases: Interim analysis. Cardiovasc Intervent Radiol. 2021;44(1):50–62. https://doi.org/10.1007/s00270-020-02646-8.

Article  PubMed  Google Scholar 

Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol. 2020;146(10):2575–87. https://doi.org/10.1007/s00432-020-03315-6.

Article  PubMed  PubMed Central  Google Scholar 

Brennan VK, Colaone F, Shergill S, Pollock RF. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. J Med Econ. 2020;23(12):1588–97. https://doi.org/10.1080/13696998.2020.1839273.

CAS  Article  PubMed  Google Scholar 

Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85. https://doi.org/10.1002/jso.20141.

CAS  Article  PubMed  Google Scholar 

Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre randomised phase 3 trials. Lancet Oncol. 2017;18(9):1159–71. https://doi.org/10.1016/S1470-2045(17)30457-6.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, et al. SIRFLOX and FOXFIRE global trial investigators. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: Combined analysis of two randomized controlled studies. Clin Colorectal Cancer. 2018;17(4):e617–29. https://doi.org/10.1016/j.clcc.2018.06.001.

Article  PubMed  Google Scholar 

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. RAISE study investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised double-blind, multicenter, phase 3 study. Lancet Oncol. 2015;16(5):499–508. https://doi.org/10.1016/S1470-2045(15)70127-0.

CAS  Article  PubMed  Google Scholar 

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. ML18147 Study Investigators Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. https://doi.org/10.1016/S1470-2045(12)70477-1.

CAS  Article  PubMed  Google Scholar 

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. https://doi.org/10.1200/JCO.2012.42.8201.

CAS  Article  PubMed  Google Scholar 

Jeyarajah DR, Doyle MBM, Espat NJ, Hansen PD, Iannitti DA, Kim J, et al. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol. 2020;11(2):443–60. https://doi.org/10.21037/jgo.2020.01.09.

Article  PubMed  PubMed Central  Google Scholar